I am often asked about the long term efficacy
J Neural Transm. 2014 May;121(5):521-30. doi: 10.1007/s00702-013-1145-3. Epub 2014 Jan 10.
Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry.
Schramm A1,
Ndayisaba JP,
Auf dem Brinke M,
Hecht M,
Herrmann C,
Huber M,
Lobsien E,
Mehnert S,
Reuter I,
Stenner A,
van der Ven C,
Winterholler M,
Kupsch A,
Wissel J.
Abstract
This study aimed at providing real-life baseline, injection and outcome data for the treatment of various forms of spasticity with onabotulinumtoxin A in Germany.
Prospective data were collected in an open multicenter patient registry from 2005 until 2010, encompassing the experience of ten specialized German centers in the treatment of spasticity using onabotulinumtoxin A in 508 patients with a total of 2005 treatment sessions.
Disease entities comprised spasticity following stroke (both ischemic and hemorrhagic), traumatic brain injury, multiple sclerosis, cerebral palsy, and anoxia. Sustained improvement was observed in a variety of outcome parameters including goal attainment and motor performance scores for up to five repeated injection sessions.
No significant differences between disease entities or between upper and lower limb treatment were observed with regard to efficacy and safety following onabotulinumtoxin A treatment.
Minor to moderate side effects were reported in <1 nbsp="" of="" population.="" span="" study="" the="">
We conclude that repetitive treatment of focal and multifocal spasticity with onabotulinumtoxin A provides a safe and efficacious therapeutic strategy for patients with different disease entities of the central nervous system.
J Child Neurol. 2014 Feb;29(2):210-3. doi: 10.1177/0883073813495306. Epub 2013 Aug 21.
Botulinum toxin type A in children and adolescents with severe cerebral palsy: a retrospective chart review.
Abstract
This retrospective cohort study reviewed set goals and their outcomes of children and adolescents with severe cerebral palsy who received botulinum toxin A in 2008 and 2009. Sixty children (36 male, mean age 9 years) were included. They received on average 4 (range 1-7) treatments, with the dosage varying between 20 and 400 units per treatment (3-21 U/kg/body weight). Mild transient side effects were reported in 12 of 242 treatments with botulinum toxin A. Treatment goals were related to lower limb function (82%), range of motion (68%), positioning (33%), upper limb function (33%), and facilitating ease of care in dressing (30%), toileting, and diapering (22%). The treatment goals were reached in 60% to 85% by report of the parent and child dyad. Our findings suggest that botulinum toxin A should be considered as a treatment option in patients with cerebral palsy within Gross Motor Function Classification System levels IV and V.
KEYWORDS:
botulinum toxin A; cerebral palsy; children; hypertonia treatment; outcome
No comments:
Post a Comment